Mylan (NASDAQ: MYL) is attempting to stabilize as investors express disappointment with the Meda deal, sending the stock in free-fall ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Mergers and Acquisitions Trader Talk

Moody's Affirms Ratings of Mylan (MYL) Amid Meda Acquisition DealFebruary 11, 2016 12:44 PM Mylan (MYL) Miss Overshadowed by Mediocre Deal - Guggenheim February 11, 2016 8:07 AM RBC Capital Views Mylan's (MYL) Meda Purchase as Desperate - PT to $58 February 11, 2016 8:05 AM Mylan to buy Swedish drugmaker Meda in $7.2 billion dealFebruary 10, 2016 4:49 PM Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30February 10, 2016 4:11 PM Mylan (MYL) Enters Agreement to Acquire Meda in ~$9.9B DealFebruary 10, 2016 4:03 PM Mylan to Acquire MedaFebruary 10, 2016 4:02 PM Mylan (MYL) to Announce Takeover of Meda - FTFebruary 10, 2016 3:47 PM